Trials / Conditions / Chemotherapy-Induced Nausea and Vomiting (CINV)

Chemotherapy-Induced Nausea and Vomiting (CINV)

11 registered clinical trials studyying Chemotherapy-Induced Nausea and Vomiting (CINV) — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting NCT07246070	AIPING ZHOU	Phase 2
Enrolling By Invitation	Evaluating the Feasibility and Acceptability of Inhalation Aromatherapy for Patients Undergoing Autologous Hae NCT07209501	Singapore General Hospital	N/A
Completed	Geranium Inhalation Aromatherapy for Reducing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy NCT07292831	Universitas Muhammadiyah Surakarta	N/A
Unknown	Safety Study of Repeat Doses of SUSTOL in Adults NCT05434663	Heron Therapeutics	Phase 4
Unknown	Granisetron Transdermal Patch for Prophylaxis of Delayed CINV NCT04912271	Fudan University	Phase 3
Unknown	Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Age NCT04472143	Fudan University	Phase 2
Completed	PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea NCT03204279	Helsinn Healthcare SA	Phase 2
Completed	Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-05 NCT01594749	Merck Sharp & Dohme LLC	Phase 3
Completed	Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183) NCT01111851	Merck Sharp & Dohme LLC	Phase 1
Completed	Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-1 NCT00952341	Merck Sharp & Dohme LLC	Phase 3
Completed	Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017) NCT00619359	Merck Sharp & Dohme LLC	Phase 3